TRT and Peptides: Can You Combine Testosterone Replacement with Peptide Therapy?

Key Takeaways

• Compounds covered: GH secretagogues (sermorelin, ipamorelin, CJC-1295), BPC-157, gonadorelin, enclomiphene, thymosin alpha-1
• Goal area: Optimizing TRT outcomes — body composition, recovery, fertility preservation, and immune support
• Evidence range: GH secretagogues have limited prospective human observational data; BPC-157 evidence is primarily preclinical; enclomiphene has retrospective clinical data; thymosin alpha-1 has extensive human observational and clinical trial data outside the US in immune-depleted populations, with no FDA-approved indication in the US.
• Regulatory range: Testosterone is a Schedule III controlled substance (21 CFR § 1308.13(f)) with multiple FDA-approved formulations. Enclomiphene is not FDA-approved — it is one isomer of clomiphene citrate (Clomid, FDA-approved for female infertility); FDA has issued Complete Response Letters on enclomiphene NDAs and has contested compounding pathways via warning letters. All other peptides discussed have compound-specific, contested, or restricted compounding statuses as detailed in the Regulatory Status section; none are FDA-approved for the combination uses described.
• Key monitoring biomarkers: Total testosterone, free testosterone, estradiol, hematocrit, IGF-1, LH, FSH, PSA, hs-CRP, comprehensive metabolic panel
• As of April 2026: Multiple FDA-approved testosterone formulations exist. None of the peptides discussed in this article are FDA-approved for use alongside TRT. Compounding status is compound-specific — sermorelin, ipamorelin, CJC-1295, gonadorelin, enclomiphene, and thymosin alpha-1 are compounded under varying and sometimes contested conditions; BPC-157 is subject to restricted compounding access as of February 2026. See the Regulatory Status at a Glance section for each compound.
• Bottom line: TRT addresses testosterone; GH secretagogues address the GH axis; BPC-157 addresses soft-tissue repair; gonadorelin addresses fertility preservation — each targets a different mechanism and requires its own monitoring framework.

Understanding the TRT + Peptide Landscape: The Biology

Testosterone replacement therapy addresses one axis of the male hormonal system: the hypothalamic-pituitary-gonadal (HPG) axis, specifically the testosterone deficiency resulting from either testicular failure or reduced hypothalamic-pituitary drive. It does not address the growth hormone axis, the immune system, musculoskeletal tissue repair mechanisms, or the fertility consequences of HPG axis suppression.

TRT is a Schedule III prescription therapy initiated only after clinical evaluation confirms hypogonadism; it is not a lifestyle optimization tool, and this article assumes readers are already under provider care for a confirmed clinical indication.

Understanding this is the basis for why combining TRT with certain peptides can be mechanistically plausible: the peptides in question target mechanisms that TRT structurally cannot address.

Status of the evidence for combining peptides with TRT

No FDA-approved peptide is approved for use in combination with testosterone replacement therapy specifically. The peptide-TRT combinations described in this article are off-label uses of individually non-FDA-approved compounds alongside a CSA-scheduled controlled substance. No controlled clinical trials have formally characterized safety or efficacy of these combinations. The mechanistic-plausibility framing in this article reflects mechanism-based reasoning and compound-individual evidence, not combination-trial evidence.

Barone and colleagues, in a 2022 International Journal of Molecular Sciences review, summarized testosterone's documented benefits in men — body composition, cardiovascular metabolic parameters, and bone density — establishing what TRT is and is not addressing. The gaps that remain after TRT optimization are the subject of the peptide adjunct discussion that follows.

The relevant gaps fall into three categories. First, the GH/IGF-1 axis: Sattler's 2013 review established that GH decline occurs independently of testosterone decline and is not corrected by TRT. Second, soft-tissue recovery: the anabolic effects of testosterone support lean mass but do not specifically target connective tissue repair pathways. Third, HPG axis fertility: TRT's suppression of gonadotropins is a direct consequence of negative feedback that GnRH-based peptides can partially counteract, a suppression Wang and Swerdloff documented in their 2022 Endocrinology and Metabolism Clinics of North America review.

Each category of peptide adjunct has its own mechanism-based rationale, evidence base, and monitoring framework; these do not substitute for combination-trial evidence, which does not exist, and are not an FDA-approved protocol.

Peptides Studied as TRT Adjuncts: A Quick Comparison

The following peptides have published evidence relevant to men on TRT. They are organized by mechanism category rather than by evidence strength, since the mechanisms address different gaps.

• Category: GH axis support
  Compounds: Sermorelin, ipamorelin, CJC-1295 (GHRH analog)
  Mechanism: Stimulate pituitary GH release; raise IGF-1; address somatopause-related body-composition and recovery deficits
  Evidence: Limited prospective human observational data (Sigalos et al. 2017, raised IGF-1 in hypogonadal men); established endocrine pharmacology
  FDA status: None FDA-approved for somatopause or as TRT adjuncts. Sermorelin was previously FDA-approved as Geref (sermorelin acetate, withdrawn for commercial reasons) and is currently compounded with status subject to FDA's position on legacy-approved bulk substances. Ipamorelin and CJC-1295 were flagged by FDA for Category 2-type safety concerns in 2023 interim determinations; both have been nominated for the 503A bulk drug substances list and compounding status is subject to FDA's evolving position. Availability varies across licensed compounding pharmacies.
  SP availability: Where offered, access is subject to clinical evaluation and provider discretion; eligibility, suitability, and prescription are determined by the licensed provider, not by Superpower.
  Route: Subcutaneous injection
• Category: Soft-tissue recovery
  Compounds: BPC-157
  Mechanism: Angiogenic, cytoprotective, and tissue-repair mechanisms in tendon, ligament, muscle, and gut; GH receptor expression enhancement in fibroblasts (in vitro; translational relevance in humans not established)
  Evidence: Primarily preclinical (rat and rabbit models); limited human case series
  FDA status: Not FDA-approved for any indication. As of February 2026, BPC-157 is subject to compounding access restrictions under FDA's updated bulk drug substance framework (reclassified from Category 2 to restricted compounding access). Availability through compounding pharmacies is limited; consult a licensed provider regarding current access.
  SP availability: Subject to the February 2026 compounding-access reclassification; not a currently offered Superpower Rx product.
  Route: Subcutaneous or oral
• Category: Fertility preservation
  Compounds: Gonadorelin, enclomiphene
  Mechanism: Gonadorelin: pulsatile GnRH analog maintaining LH/FSH drive. Enclomiphene: selective estrogen receptor modulator (SERM) blocking hypothalamic negative feedback, stimulating endogenous LH and testosterone
  Evidence: Gonadorelin: established endocrine pharmacology for its on-label use; fertility-preservation on TRT is off-label and compounded. Enclomiphene: retrospective clinical comparison data (Thomas et al. 2023, Cureus)
  FDA status: Gonadorelin: not FDA-approved for fertility preservation on TRT; formerly available as FDA-approved products (Factrel, Lutrepulse) that have been withdrawn. Currently compounded; availability subject to FDA's position on legacy-approved bulk substances. Enclomiphene: not FDA-approved. FDA received NDA submissions for enclomiphene citrate (Repros Therapeutics, Androxal) and issued Complete Response Letters; enclomiphene is one isomer of clomiphene citrate (Clomid), which is FDA-approved for female infertility. Some compounding pharmacies compound enclomiphene on the theory that it is a "component" of an approved drug under 21 U.S.C. § 353a(b)(1)(A)(ii); FDA has contested this interpretation in warning letters.
  SP availability: Where offered, access is subject to clinical evaluation and provider discretion; eligibility, suitability, and prescription are determined by the licensed provider, not by Superpower.
  Route: Gonadorelin: subcutaneous injection. Enclomiphene: oral
• Category: Immune support
  Compounds: Thymosin alpha-1
  Mechanism: Immunomodulatory; supports T-cell maturation and innate immune function; well-characterized in oncology and infection contexts
  Evidence: Extensive human data in immune-depleted populations; Dinetz and Lee 2024 summarized published human trials
  FDA status: Not FDA-approved in the US. FDA has classified thymosin alpha-1 among bulk substances with significant safety concerns in its 2023 Category 2 determinations. Some compounding pharmacies continue to compound thymosin alpha-1 under contested regulatory conditions.
  SP availability: Where offered, access is subject to clinical evaluation and provider discretion; eligibility, suitability, and prescription are determined by the licensed provider, not by Superpower.
  Route: Subcutaneous injection

Peptides That Complement TRT: Individual Profiles

Each peptide category addresses a different gap in the TRT picture. Their mechanisms do not overlap with testosterone's androgen receptor pathway, which is why combining them is mechanistically distinct from simply adding more testosterone.

GH secretagogues (sermorelin, ipamorelin, CJC-1295)

GH secretagogues are peptides that stimulate the pituitary gland to release endogenous growth hormone, as distinct from exogenous GH administration. The most clinically studied in this context are sermorelin (a GHRH analog), ipamorelin (a ghrelin receptor agonist), and CJC-1295 (a modified GHRH analog with extended half-life).

For men on TRT, the rationale for GH secretagogue addition is somatopause: the age-related decline in GH and IGF-1 that occurs independently of testosterone and is not addressed by TRT. Sinha and colleagues, in a 2020 Translational Andrology and Urology review, reviewed GH secretagogues as adjuncts to testosterone therapy, covering body composition improvements and the rationale for addressing both axes simultaneously. Sigalos and colleagues, in a 2017 American Journal of Men's Health prospective study, demonstrated that GH secretagogues raise IGF-1 levels in hypogonadal men, confirming that GH axis stimulation is achievable even in the context of testosterone deficiency. Di Somma and colleagues' 2011 somatopause review documented that declining GH produces body-composition and metabolic consequences distinct from those driven by low testosterone, supporting the clinical rationale for addressing both axes. [Limited prospective human data]

GH secretagogues are not FDA-approved for somatopause or as TRT adjuncts. They have been nominated for inclusion on the FDA's 503A bulk drug substances list, and as of April 2026 their compounding status remains subject to FDA's evolving position on peptide bulk substances; availability through compounding pharmacies varies. Where Superpower offers access, it is subject to clinical evaluation and provider discretion — eligibility, suitability, and prescription are determined by the licensed provider, not by Superpower. IGF-1 monitoring at baseline and 3–6 months into therapy is standard clinical practice when adding a GH secretagogue, as IGF-1 is the most clinically useful marker for GH axis response. Kościuszko and colleagues, in a 2026 International Journal of Molecular Sciences 24-month GH intervention study, showed cardiovascular and body-composition improvements with GH intervention, providing supporting context for IGF-1 monitoring rationale during secretagogue therapy.

BPC-157

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in gastric juice. It is studied primarily for soft-tissue repair: tendon, ligament, muscle, bone, and gut barrier function.

For men on TRT — who are often engaged in resistance training or demanding physical activity — BPC-157's proposed mechanism of supporting connective tissue and musculoskeletal repair has been proposed as a potential adjunct for a gap that testosterone alone does not fill, though human evidence is limited. Seiwerth and colleagues, in a 2021 Frontiers in Pharmacology systematic review, summarized BPC-157's wound-healing and tissue-repair properties across multiple tissue types. Gwyer and colleagues, in a 2019 Cell and Tissue Research review, specifically covered BPC-157's role in accelerating musculoskeletal soft-tissue healing including tendon and ligament repair. Seiwerth and colleagues, in an earlier 2018 Current Pharmaceutical Design review, characterized BPC-157's angiogenic and healing mechanisms across tendon, ligament, bone, and muscle.

A mechanistically interesting intersection with the GH axis: Chang and colleagues, in a 2014 Molecules study, showed BPC-157 enhances growth hormone receptor expression in tendon fibroblasts — linking BPC-157 and GH signaling at the tissue level, potentially explaining part of its tissue-repair activity. Cerovecki and colleagues, in a 2010 Journal of Orthopaedic Research study, demonstrated BPC-157 improved medial collateral ligament healing in rat models as rigorous preclinical evidence for soft-tissue repair. [Primarily preclinical; limited human case series]

BPC-157 is not FDA-approved for any indication. Evidence in humans is limited to a case series by Lee and colleagues (2021, Alternative Therapies in Health and Medicine, intra-articular BPC-157 for knee pain) and individual case reports. Its evidence is primarily preclinical. As of February 2026, BPC-157 is subject to compounding access restrictions under FDA's updated bulk drug substance framework; availability through compounding pharmacies is limited. Consult a licensed provider regarding current availability. No specific additional biomarker monitoring is required beyond a standard comprehensive metabolic panel as a safety baseline.

Gonadorelin and enclomiphene (fertility preservation)

Testosterone replacement therapy suppresses LH and FSH through negative feedback on the HPG axis, which reduces intratesticular testosterone production and spermatogenesis. For men who want to preserve fertility on TRT, gonadorelin (a pulsatile GnRH analog) and enclomiphene (a selective estrogen receptor modulator) represent two approaches to maintaining some HPG axis activity.

Wang and Swerdloff's 2022 Endocrinology and Metabolism Clinics of North America review documented the fertility risk from TRT-induced gonadotropin suppression. Moss and colleagues, in a 2013 Fertility and Sterility review, reviewed the effects of rejuvenation hormones on spermatogenesis, establishing the clinical need for fertility-preserving strategies in men on hormone therapy. Gonadorelin maintains pulsatile LH and FSH drive; Earl and colleagues in a 2019 Expert Review of Endocrinology and Metabolism review covered enclomiphene as a fertility-maintaining treatment for secondary hypogonadism. Thomas and colleagues, in a 2023 Cureus retrospective study, reported a larger mean testosterone response for enclomiphene than for clomiphene in the retrospective cohort, though retrospective data cannot establish superiority, in fertility-focused male hypogonadism management. Rodriguez and colleagues, in a 2016 Expert Opinion on Pharmacotherapy review, reviewed enclomiphene's mechanism of HPG axis stimulation as an example of endogenous production preservation. Evidence for enclomiphene as a standalone treatment is limited to retrospective and observational data; randomized controlled trials supporting long-term fertility and testosterone outcomes are not available. [Established endocrine pharmacology for gonadorelin's on-label use; off-label compounded use for TRT fertility preservation; retrospective data for enclomiphene]

Gonadorelin was formerly available as FDA-approved products (Factrel, Lutrepulse) that have been withdrawn; it is currently compounded under a contested pathway. Enclomiphene has received Complete Response Letters from FDA on NDA submissions; compounding is based on a contested interpretation of 21 U.S.C. § 353a(b)(1)(A)(ii) for which FDA has issued warning letters. Where Superpower offers access to either compound, it is subject to clinical evaluation and provider discretion — eligibility, suitability, and prescription are determined by the licensed provider, not by Superpower. Monitoring for men using these compounds alongside TRT includes LH, FSH, and semen analysis, in addition to standard TRT monitoring.

Thymosin alpha-1

Thymosin alpha-1 is a 28-amino-acid peptide derived from the thymus that modulates T-cell maturation and innate immune function. It is among the most clinically documented thymic peptides, with extensive human data primarily from oncology, viral hepatitis, and critical illness contexts.

For men on TRT, thymosin alpha-1 addresses immune function — a domain that testosterone influences (supraphysiological testosterone is mildly immunosuppressive) but does not specifically optimize. Dinetz and Lee, in a 2024 Alternative Therapies in Health and Medicine review, summarized thymosin alpha-1 safety and efficacy across published human trials, and Wang and colleagues' 2016 systematic review and meta-analysis in BioMed Research International provides higher-tier evidence on thymosin alpha-1 clinical outcomes in sepsis. Matteucci and colleagues, in a 2023 International Immunopharmacology study, characterized thymosin alpha-1's mechanism of action including immune modulation pathways. [Extensive human observational and clinical trial data outside the US in immune-depleted populations; no FDA-approved indication in the US; not studied specifically as a TRT adjunct]

Thymosin alpha-1 is not FDA-approved in the US. FDA has classified thymosin alpha-1 among bulk substances with significant safety concerns in its 2023 Category 2 determinations; some compounding pharmacies continue to compound thymosin alpha-1 under contested regulatory conditions. Where Superpower offers access, it is subject to clinical evaluation and provider discretion — eligibility, suitability, and prescription are determined by the licensed provider, not by Superpower. No specific additional monitoring is required beyond the standard TRT panel for this addition.

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article have compound-specific and often contested regulatory statuses. None are FDA-approved for combination use with TRT.

• Testosterone replacement therapy (TRT): Testosterone is a Schedule III controlled substance under the federal Controlled Substances Act (21 CFR § 1308.13(f)). Multiple FDA-approved testosterone formulations exist (cypionate, enanthate, topical gels, patches, pellets). As a CSA-scheduled drug, TRT requires prescription by a DEA-registered provider, is subject to refill and record-keeping limitations under 21 CFR § 1306.22, and in most states is subject to controlled substance prescription monitoring program reporting. Telehealth prescribing of testosterone is subject to federal and state-level controlled substance prescribing rules, which vary by jurisdiction.
• Sermorelin: Not FDA-approved for somatopause or as a TRT adjunct. Previously marketed as FDA-approved Geref (sermorelin acetate), which was withdrawn for commercial rather than safety/efficacy reasons; currently compounded, with status subject to FDA's position on legacy-approved bulk substances.
• Ipamorelin, CJC-1295: Not FDA-approved. FDA signaled Category 2-type safety concerns for ipamorelin and CJC-1295 in 2023 interim bulk drug substance determinations; both compounds have been nominated for inclusion on the FDA's 503A bulk drug substances list, and as of April 2026 their compounding status remains subject to FDA's evolving position on peptide bulk substances. Some licensed compounding pharmacies compound these peptides; availability varies.
• BPC-157: Not FDA-approved for any indication. As of February 2026, BPC-157 is subject to compounding access restrictions under FDA's updated bulk drug substance framework (reclassified from Category 2 to restricted compounding access). Availability through compounding pharmacies is limited; evidence is primarily preclinical.
• Gonadorelin: Not FDA-approved for fertility preservation on TRT. Formerly available as FDA-approved products (Factrel, Lutrepulse) that have been withdrawn. Currently compounded; availability subject to FDA's position on legacy-approved bulk substances.
• Enclomiphene: Not FDA-approved. FDA received NDA submissions for enclomiphene citrate (Repros Therapeutics, Androxal) and issued Complete Response Letters; enclomiphene is one isomer of clomiphene citrate (Clomid), which is FDA-approved for female infertility. Some compounding pharmacies compound enclomiphene on the theory that it is a "component" of an approved drug under 21 U.S.C. § 353a(b)(1)(A)(ii); FDA has contested this interpretation in warning letters. Availability varies.
• Thymosin alpha-1: Not FDA-approved in the US. FDA has classified thymosin alpha-1 among bulk substances with significant safety concerns in its 2023 Category 2 determinations. Some compounding pharmacies continue to compound thymosin alpha-1 under contested regulatory conditions.

Considerations When Adding Peptides to TRT

The clinical decision to add a peptide to an existing TRT protocol involves more than choosing a compound. Direct cross-peptide comparisons are not available from comparative trials; these compounds have been studied separately in different populations using different endpoints.

Identify the specific gap first: Is the limitation body composition and recovery despite optimized testosterone? Or is it persistent fatigue from GH axis decline? Or a fertility concern? The answer should precede any compound discussion. Adding a GH secretagogue to a man who has normal IGF-1 levels addresses a problem that does not exist in his physiology.

Baseline biomarker profile: The value of baseline testing before adding any peptide is that it identifies whether a gap actually exists. IGF-1 below the reference range provides evidence for GH axis insufficiency; normal IGF-1 means the GH axis is not the limiting factor. LH and FSH characterize the degree of HPG suppression from TRT and whether fertility-preserving agents are appropriate.

Evidence level comfort: BPC-157's evidence is primarily preclinical. GH secretagogues have human trial data. Thymosin alpha-1 has extensive human safety data. A provider will factor in how much clinical evidence supports a compound before recommending it, particularly when adding to an existing therapeutic protocol.

Monitoring complexity: Adding compounds to a TRT protocol increases the monitoring burden. Each addition should have a rationale, a monitoring biomarker, and a defined reassessment timeline.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate full health history, TRT optimization status, current medications, and baseline lab values before recommending any additional compound.

Safety Considerations

Safety for combinations depends on the compound categories involved. The interactions between these peptides and testosterone are not formally characterized in controlled trials; clinical experience and mechanism-based reasoning are the current framework.

The most important safety consideration specific to TRT is erythrocytosis: TRT raises hematocrit, and this effect may be additive with GH secretagogues in some individuals. The Endocrine Society clinical practice guideline by Bhasin and colleagues (2018) in the Journal of Clinical Endocrinology and Metabolism defines the monitoring framework for testosterone therapy in hypogonadal men including hematocrit thresholds. Regular hematocrit monitoring is standard on TRT; adding a GH secretagogue does not eliminate this requirement.

Contraindications that apply broadly to peptide additions to TRT include:

• Active hormone-sensitive malignancy — both testosterone and GH secretagogues carry theoretical proliferative concerns; oncology clearance is required
• Uncontrolled cardiovascular disease — multiple compounds in this list have hemodynamic or metabolic effects that require clinical evaluation
• Prostate cancer history or elevated PSA without evaluation — testosterone and GH axis stimulation both require prostate safety monitoring
• Pregnancy planning without provider guidance — TRT suppresses spermatogenesis; adding fertility-preserving agents without coordination can complicate clinical management
• Unmonitored self-directed compound combinations — the absence of baseline labs and provider oversight creates genuine risk that individual compound profiles cannot capture

For compound-specific side effect profiles, see the individual compound pages linked above.

What to Test Before Adding Peptides to TRT

Regardless of which peptide is being considered, baseline biomarker testing before any addition establishes whether the target axis is actually suboptimal and provides a reference point for assessing response.

• IGF-1: The primary marker of GH axis activity. IGF-1 below the reference range supports a rationale for GH secretagogue addition; normal IGF-1 means the GH axis is not the relevant gap. Jakobsdóttir and colleagues linked IGF-1 to body composition in a 2010 community-based study confirming its relevance as a monitoring marker.
• Total and free testosterone: Confirm that TRT is adequately optimized before adding any adjunct. Persistent symptoms may indicate suboptimal TRT dosing rather than requiring additional compounds. Total testosterone and free testosterone together establish this baseline.
• Estradiol: Aromatization of testosterone to estradiol is common on TRT; elevated estradiol affects libido, mood, and bone metabolism. Estradiol baseline is standard TRT monitoring.
• Hematocrit: Erythrocytosis is the most common TRT-related adverse effect requiring monitoring. Adding GH secretagogues does not eliminate this risk. Hematocrit at baseline and every 3–6 months is standard.
• LH and FSH: If fertility is a concern, LH and FSH characterize the degree of HPG suppression from TRT and inform whether gonadorelin or enclomiphene coadministration is appropriate.
• hs-CRP: Systemic inflammation baseline is useful context for any compound addition. hs-CRP at baseline allows detection of inflammation changes during therapy.
• PSA: Prostate safety baseline is mandatory for any man on TRT and is relevant when adding GH secretagogues. Testing total PSA and free PSA establishes the baseline required for ongoing safety monitoring.
• Comprehensive metabolic panel: Liver and kidney safety baseline for any new compound; standard with every TRT monitoring cycle.

Total testosterone, free testosterone, estradiol, hematocrit, IGF-1, LH, FSH, PSA, and hs-CRP together provide the monitoring baseline that makes any peptide addition to TRT clinically interpretable. Testing through a comprehensive testosterone and hormonal panel establishes this data before any provider conversation about adding peptides to TRT.

How to Access These Peptides Safely

All peptides discussed in this article require prescriptions from licensed healthcare providers. Access pathways include telehealth with a prescribing provider experienced in TRT management, subject to federal DEA telemedicine controlled-substance rules (21 U.S.C. § 829(e) and the DEA's current telemedicine rulemaking) and applicable state-level controlled substance prescribing rules, followed by dispensing through licensed compounding pharmacies. Where Superpower facilitates access, it is subject to clinical evaluation and provider discretion; eligibility, suitability, and prescription are determined by the licensed provider, not by Superpower.

A provider conversation about adding peptides to TRT typically involves: a review of current TRT optimization status with lab confirmation, identification of which gap or limitation the patient is experiencing, baseline biomarker evaluation for the relevant axis, and a discussion of evidence levels and monitoring requirements for the specific compound under consideration.

Self-directed peptide additions to TRT without provider oversight create particular risk: monitoring complexity increases with each addition, potential interactions with TRT require experienced clinical assessment, and the absence of baseline labs means there is no objective way to determine whether a compound is producing the intended effect or an unintended one.

Understanding Your Baseline

Men on TRT are already engaged in evidence-based hormonal optimization. The question of whether to add peptides is a question about which axes remain unaddressed — and the answer requires data, not assumptions. IGF-1 levels, LH/FSH suppression, tissue recovery trajectory, and inflammatory markers each tell a different part of the story.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider confirms TRT optimization is complete, identifies a GH axis deficit worth addressing, or reveals that a fertility-preservation strategy is appropriate, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

Testosterone is a Schedule III controlled substance under the federal Controlled Substances Act (21 CFR § 1308.13(f)). Prescribing is subject to DEA and state controlled substance regulations, including refill and record-keeping limits under 21 CFR § 1306.22 and telemedicine rules under the Ryan Haight Act (21 U.S.C. § 829(e)) and the DEA's current telemedicine rulemaking. Multiple FDA-approved testosterone formulations exist (cypionate, enanthate, topical gels, patches, pellets); full prescribing information for each approved formulation is available in FDA-approved labeling. All peptides discussed in this article as TRT adjuncts — including GH secretagogues (sermorelin, ipamorelin, CJC-1295), BPC-157, gonadorelin, enclomiphene, and thymosin alpha-1 — are not FDA-approved for use as TRT adjuncts. Their use in combination with TRT is off-label, and no controlled clinical trials have characterized safety or efficacy of these combinations. Superpower Health's offerings vary by compound. BPC-157 is not a currently offered Superpower Rx product. Where Superpower Health does offer access to compounded peptides discussed in this article, access is through licensed healthcare providers and compounding pharmacy partners, is subject to clinical evaluation and provider discretion, and is determined by the licensed provider, not by Superpower.

GH secretagogues (sermorelin, ipamorelin, CJC-1295): Not FDA-approved for any indication. Nominated for inclusion on the FDA's 503A bulk drug substances list; compounding status remains subject to FDA's evolving position on peptide bulk substances (FDA signaled Category 2-type safety concerns for ipamorelin and CJC-1295 in 2023 determinations). Safety and efficacy as TRT adjuncts have not been established through adequate and well-controlled clinical trials. Requires IGF-1 monitoring at baseline and during therapy. Growth hormone secretagogues (including GHRH analogs and GHRP/ghrelin mimetics) are listed on the WADA Prohibited List under Category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and are prohibited at all times (in-competition and out-of-competition) for athletes subject to WADA Code compliance.

BPC-157: Not approved by the FDA for any medical use. Research on this compound has been limited primarily to animal studies, with limited human case series data. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. As of February 2026, BPC-157 is subject to compounding access restrictions under FDA's updated bulk drug substance framework; availability through compounding pharmacies is limited. Consult a licensed provider regarding current availability.

Gonadorelin: Not FDA-approved for fertility preservation on TRT. Formerly available as FDA-approved products (Factrel, Lutrepulse) that have been withdrawn. Currently compounded under a contested pathway; availability subject to FDA's position on legacy-approved bulk substances. Safety and efficacy for this use have not been established through adequate and well-controlled clinical trials.

Enclomiphene: Not FDA-approved. FDA received NDA submissions for enclomiphene citrate (Repros Therapeutics, Androxal) and issued Complete Response Letters. Enclomiphene is one isomer of clomiphene citrate (Clomid), which is FDA-approved for female infertility. Some compounding pharmacies compound enclomiphene on the theory that it is a "component" of an approved drug under 21 U.S.C. § 353a(b)(1)(A)(ii); FDA has contested this interpretation in warning letters. Safety and efficacy for male hypogonadism management have not been established through FDA approval.

Thymosin alpha-1: Not FDA-approved in the US for any indication, including as a TRT adjunct. FDA classified thymosin alpha-1 among bulk substances with significant safety concerns in its 2023 Category 2 interim determinations. Human observational and clinical trial data exist for immune-depleted populations outside the US; these data have not been evaluated by FDA for US marketing authorization and do not establish safety or efficacy for use as a TRT adjunct.

Warnings: Regular monitoring of hematocrit, testosterone levels, estradiol, PSA, and IGF-1 (when applicable) is required for safe TRT management with or without peptide adjuncts. Do not add compounds to a TRT protocol without provider oversight. Unmonitored compound combinations can produce unexpected metabolic and hormonal changes. Men with prostate cancer, active cardiovascular disease, or hormone-sensitive malignancy should not add GH secretagogues or testosterone analogs without specialist clearance.

Full FDA-approved prescribing information for the testosterone formulations referenced above is available at dailymed.nlm.nih.gov. No FDA-approved prescribing information exists for the peptides discussed in this article as TRT adjuncts, because none of these peptides is FDA-approved for this use.